
    
      Metastatic breast cancer patients previously treated with anthracyclines and taxanes will be
      treated with gemcitabine and carboplatin every 3 weeks. Serial plasma samples will be
      collected for proteomics profiling with SELDI-MS that will be correlated with tumor response
      to identify biomarkers that may predict for chemotherapy sensitivity.
    
  